LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer
Interventions: COMBINATION_PRODUCT: Drug 1: LY3023414; Drug 2: Prexasertib
Sponsor: Baylor Research Institute
Collaborators: Eli Lilly and Company